Global /South Korea /Healthcare /Drug Manufacturers - General /141080

LigaChem Biosciences Inc.

141080

• KRX: 141080 • Delayed

183,400KRW -5.7%

120.17 USD

As of 11 June 2026, LigaChem Biosciences Inc. has a market cap of $4.44B USD, ranking #4150 globally and #104 in South Korea. It ranks #312 in the Healthcare sector, and #119 in the Drug Manufacturers - General industry.

Global Rank

4150

Country Rank

104

Sector Rank

312

Industry Rank

119

Key Stats

Market Cap

$4.44BUSD

6.76T KRW

Enterprise Value

$4.14BUSD

6.32T KRW

Revenue (TTM)

$93.04MUSD

141.55B KRW

EBITDA (TTM)

-$65.44MUSD

-99.88B KRW

Net Income (TTM)

-$48.82MUSD

-74.28B KRW

EBITDA Margin

-71%

Profit Margin

-52%

PS Ratio

47.7

PB Ratio

12.5

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Yong Kim open_in_new

Employees

170

Founded

2006

Website

ligachembio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-5.7%	3.3%	-8.9%	-4%	35%	12%	85%	410%	281%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	141080 LigaChem Biosciences Inc ISIN: KR7141080002 Shares Out.: Shares Outstanding: 36.849M¹ Shares Float: 25.904M² TV: TradingView: KRX: 141080 SA: Stock Analysis: KRX: 141080 YF: Yahoo Finance: 141080.KS GF: Google Finance: KRX: 141080 BA: Barron's: 141080 MS: Morningstar: XKRX: 141080	183,400 KRW	TV: TradingView: KRX: 141080 SA: Stock Analysis: KRX: 141080 YF: Yahoo Finance: 141080.KS GF: Google Finance: KRX: 141080 BA: Barron's: 141080 MS: Morningstar: XKRX: 141080

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About LigaChem Biosciences Inc.

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.14B 13.91T KRW 106%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.77B 10.3T KRW 52%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.24B 7.97T KRW 18%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.96B 7.55T KRW 12%	-	South Korea
Yuhan Corp. KRX: 000100	$4.55B 6.92T KRW 2.4%	35.9	South Korea
Hanmi Pharm. Co., Ltd. KRX: 128940	$4.03B 6.12T KRW -9.4%	36.1	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 17K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 12K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 8K%	97.4	United States
Roche Holding AG SIX: RO	$320.56B 256.25B CHF 7K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.45B 215.59B GBP 6K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 6K%	15.1	United States

chevron_leftBack